NovAliX provides drug discovery services from screening to optimized leads—with strong expertise in medicinal chemistry and computational capabilities combined with screening platforms: (covalent) fragments & DNA-encoded libraries. Experts provide in vitro pharmacology services and a unique biophysical and structural platform encompassing MS, SPR, NMR, MST, DSF, HDX, X-ray crystallography & cryo-EM — including membrane proteins. NovAliX also provides research services in synthetic chemistry and chemical processes including flow-chemistry.

Founded in 2002 and based in Strasbourg, France, with around 230 researchers—NovAliX has three sites that allow it to provide innovative and flexible drug discovery solutions. NovAliX offers its clients original collaborative models and extensive services within the framework of research programs dedicated to drug discovery. Its ambition is to continue its development by both strengthening its internationalization and extending and integrating the new capabilities essential to the success of its clients' therapeutic research projects into its technologies and base of expertise.